Should You Buy EyePoint Inc (EYPT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
EYPT is NOT a good buy right now for a beginner, long-term investor who is impatient and doesn’t want to wait for cleaner entry timing. The chart is weakening (bearish momentum), there are no near-term news/catalysts, and the business is still highly biotech/clinical-outcome dependent with very weak current revenue trends. While Wall Street (notably Mizuho) remains bullish on the long-term Duravyu thesis, the current setup looks more like a “wait” than an immediate long-term buy.
Technical Analysis
Price closed at 15.34 (-4.87% vs prior close 15.81) with a small post-market rebound (+1.99%), suggesting dip-buying interest but not a confirmed reversal. Momentum is bearish: MACD histogram is negative (-0.171) and expanding downward, indicating the down-move is strengthening. RSI(6) at 36.6 is approaching oversold but still in the neutral/weak zone—this often signals downside pressure remains even if a short bounce occurs. Moving averages are converging (no strong trend support), which often precedes a larger move but does not confirm direction—MACD currently favors downside. Key levels: Support S1 ~14.706 (important near-term ‘must-hold’ level); below that S2 ~13.974. Resistance: pivot ~15.893 (needs to reclaim for stabilization), then R1 ~17.079. Net: trend/momentum currently unfavorable for an impatient long-term entry.
Analyst Ratings and Price Target Trends
Recent trend: limited coverage in the provided data, but what is shown is consistently positive from Mizuho. On 2025-11-11, Mizuho called the pullback a buying opportunity, kept an Outperform rating, and set a $33 target. On 2025-12-09, Mizuho again remained Outperform, expressing comfort in EyePoint’s Phase 3 approach and seeing minimal negative read-through from a competitor’s accelerated NDA plans. Wall Street pros: strong upside if Duravyu succeeds, and at least one notable analyst is firmly constructive. Wall Street cons: the story is still clinical/timeline driven with competitive noise, and current fundamentals do not provide stability—so timing and risk tolerance matter more than usual.
Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.5 USD with a low forecast of 20 USD and a high forecast of 43 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.5 USD with a low forecast of 20 USD and a high forecast of 43 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 15.040
Current: 15.040
